![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PQBP1 |
Gene summary for PQBP1 |
![]() |
Gene information | Species | Human | Gene symbol | PQBP1 | Gene ID | 10084 |
Gene name | polyglutamine binding protein 1 | |
Gene Alias | MRX2 | |
Cytomap | Xp11.23 | |
Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | A0A0S2Z4V5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10084 | PQBP1 | LZE4T | Human | Esophagus | ESCC | 1.56e-14 | 5.58e-01 | 0.0811 |
10084 | PQBP1 | LZE7T | Human | Esophagus | ESCC | 3.01e-10 | 5.38e-01 | 0.0667 |
10084 | PQBP1 | LZE8T | Human | Esophagus | ESCC | 2.87e-07 | 1.40e-01 | 0.067 |
10084 | PQBP1 | LZE20T | Human | Esophagus | ESCC | 9.89e-06 | 3.49e-01 | 0.0662 |
10084 | PQBP1 | LZE22D1 | Human | Esophagus | HGIN | 3.31e-02 | -8.38e-02 | 0.0595 |
10084 | PQBP1 | LZE22T | Human | Esophagus | ESCC | 2.84e-04 | 1.56e-01 | 0.068 |
10084 | PQBP1 | LZE24T | Human | Esophagus | ESCC | 3.39e-15 | 4.19e-01 | 0.0596 |
10084 | PQBP1 | LZE21T | Human | Esophagus | ESCC | 1.47e-08 | 3.19e-01 | 0.0655 |
10084 | PQBP1 | LZE6T | Human | Esophagus | ESCC | 2.30e-09 | 1.80e-01 | 0.0845 |
10084 | PQBP1 | P1T-E | Human | Esophagus | ESCC | 2.11e-12 | 6.60e-01 | 0.0875 |
10084 | PQBP1 | P2T-E | Human | Esophagus | ESCC | 1.17e-40 | 9.57e-01 | 0.1177 |
10084 | PQBP1 | P4T-E | Human | Esophagus | ESCC | 5.24e-34 | 8.72e-01 | 0.1323 |
10084 | PQBP1 | P5T-E | Human | Esophagus | ESCC | 4.36e-32 | 5.80e-01 | 0.1327 |
10084 | PQBP1 | P8T-E | Human | Esophagus | ESCC | 1.02e-45 | 9.03e-01 | 0.0889 |
10084 | PQBP1 | P9T-E | Human | Esophagus | ESCC | 4.21e-29 | 7.52e-01 | 0.1131 |
10084 | PQBP1 | P10T-E | Human | Esophagus | ESCC | 1.44e-22 | 4.34e-01 | 0.116 |
10084 | PQBP1 | P11T-E | Human | Esophagus | ESCC | 4.05e-13 | 8.39e-01 | 0.1426 |
10084 | PQBP1 | P12T-E | Human | Esophagus | ESCC | 5.19e-26 | 5.96e-01 | 0.1122 |
10084 | PQBP1 | P15T-E | Human | Esophagus | ESCC | 6.45e-37 | 8.44e-01 | 0.1149 |
10084 | PQBP1 | P16T-E | Human | Esophagus | ESCC | 7.03e-38 | 7.82e-01 | 0.1153 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004333111 | Thyroid | ATC | response to dsRNA | 27/6293 | 55/18723 | 1.24e-02 | 4.38e-02 | 27 |
GO:005077312 | Thyroid | ATC | regulation of dendrite development | 46/6293 | 103/18723 | 1.26e-02 | 4.42e-02 | 46 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0304018 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
hsa0304019 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
hsa0304026 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
hsa0304036 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PQBP1 | SNV | Missense_Mutation | novel | c.755T>C | p.Leu252Pro | p.L252P | O60828 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PQBP1 | SNV | Missense_Mutation | novel | c.547G>A | p.Glu183Lys | p.E183K | O60828 | protein_coding | deleterious(0.01) | benign(0.091) | TCGA-B6-A0RL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PQBP1 | SNV | Missense_Mutation | novel | c.125N>T | p.Ala42Val | p.A42V | O60828 | protein_coding | tolerated(0.11) | probably_damaging(0.978) | TCGA-BH-A0H9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PQBP1 | SNV | Missense_Mutation | c.415G>A | p.Asp139Asn | p.D139N | O60828 | protein_coding | tolerated(0.26) | possibly_damaging(0.453) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
PQBP1 | SNV | Missense_Mutation | rs782092434 | c.647N>T | p.Thr216Met | p.T216M | O60828 | protein_coding | deleterious(0.01) | possibly_damaging(0.828) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PQBP1 | SNV | Missense_Mutation | c.79N>C | p.Glu27Gln | p.E27Q | O60828 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
PQBP1 | SNV | Missense_Mutation | novel | c.676G>A | p.Glu226Lys | p.E226K | O60828 | protein_coding | deleterious(0.02) | probably_damaging(0.98) | TCGA-ZJ-AAXA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PQBP1 | SNV | Missense_Mutation | c.270N>T | p.Lys90Asn | p.K90N | O60828 | protein_coding | tolerated(0.06) | probably_damaging(0.987) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PQBP1 | SNV | Missense_Mutation | novel | c.239N>C | p.Asp80Ala | p.D80A | O60828 | protein_coding | deleterious(0.02) | probably_damaging(0.991) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
PQBP1 | SNV | Missense_Mutation | rs782634968 | c.529C>T | p.Arg177Cys | p.R177C | O60828 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |